Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model.

Yun-Ti Chen,Yu-Hsiu Chang,Nikhil Pathak,Shey-Cherng Tzou,Yong-Chun Luo,Yen-Chao Hsu,Tian-Neng Li,Jung-Yu Lee,Yi-Cyun Chen,Yu-Wei Huang, Hsin-Ju Yang,Nung-Yu Hsu,Hui-Ping Tsai,Tein-Yao Chang,Shu-Chen Hsu,Ping-Cheng Liu,Yuan-Fan Chin,Wen-Chin Lin,Chuen-Mi Yang,Hsueh-Ling Wu,Chia-Ying Lee, Hui-Ling Hsu, Yi-Chun Liu,Jhih-Wei Chu,Lily Hui-Ching Wang, Jann-Yuan Wang,Chih-Heng Huang, Chi-Hung Lin,Po-Shiuan Hsieh,Yan-Hwa Wu Lee,Yi-Jen Hung,Jinn-Moon Yang

Frontiers in immunology（2022）

引用 0|浏览4

暂无评分

摘要

We demonstrate that this systematic repurposing approach is potentially useful to identify pharmaceutical targets, multi-target drugs and regulated pathways for a complex disease. Our findings indicate that methotrexate is established as a promising drug against SARS-CoV-2 variants and can be used to treat lung damage and inflammation in COVID-19, warranting future evaluation in clinical trials.

查看译文

关键词

SARS-CoV-2,drug repurposing,inflammation,methotrexate,multi-target drugs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要